A Phase 2 interventional study of XELOX and Capecitabine monotherapy in Advanced Rectal Cancer, sponsored by Zhen-Hai Lu. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-22.
Sponsored by Zhen-Hai Lu · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing xelox in Rectal Neoplasms — 6 open to participants now, 8 under way, 1 of them phase 3. xelox · Rectal Neoplasms.
Among the 16 studies testing xelox in Rectal Neoplasms, this one is the 6th largest by planned enrollment, is one of 3 that started in 2022, is one of 13 in phase 2, and was the 11th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →6 of the 16 studies testing xelox in Rectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:
fan li · Sites in China
Ages 18–80
Ruijin Hospital · Sites in China
Ages 18–75
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Sites in China
Ages 18–75
Fudan University · Sites in China
Ages 18–75
Tang-Du Hospital
Ages 18–70
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 121 is above the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 82 across the 16 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Zhen-Hai Lu as lead sponsor.
Zhen-Hai Lu has 1 study filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies testing xelox in Rectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05228431Zhen-Hai LuModified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing xelox in Rectal Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the treatment of locally advanced rectal cancer, the short-term and long-term efficacy of the traditional sandwich regimen has not reached satisfactory efficacy. For this reason, the concept of reducing the dose of postoperative chemotherapy or directly moving forward the full amount of postoperative chemotherapy was proposed, which is called total neoadjuvant therapy (TNT). However, TNT also includes the high toxicity of oxaliplatin in the whole process and the long time interval between the end of radiotherapy and the operation, which leads to fibrosis of the surrounding tissue, which increases the difficulty of surgical resection and makes it difficult to ensure good surgical specimen quality. In addition to this, there are issues that may increase the risk of potential disease progression in patients with poor treatment withdrawal. Therefore, appropriately reducing the intensity of chemotherapy and controlling the total duration of preoperative neoadjuvant therapy during radiotherapy is expected to alleviate the side effects of neoadjuvant therapy. Here, the investigators synthesized the characteristics of TNT and sandwich regimens and proposed a XELOX regimen and capecitabine alternate administration combined with preoperative intensity modulated radiation therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pathological confirmed rectal adenocarcinoma.
Clinical stage T3-4 or T any N1.With or without MRF positivity, with or without EMVI positivity, R0 resection is estimated.
No
No signs of intestinal obstruction; or intestinal obstruction has been relieved after proximal colostomy surgery.
Age ranged from 18 to 75
No previous radiotherapy,surgery and chemotherapy.
Exclusion Criteria:
Multiple primary tumor
Cachexy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All rectal patients in this group will receive standard surgical resection.
Drug: XELOX · Drug: Capecitabine monotherapy · Radiation: Radiation
Starting from the first day of radiotherapy (set as day 0), the patient received a total of 4 courses of XELOX chemotherapy on days -42, -21, 42, and 63, including oxaliplatin 130 mg/m2, intravenous administration, d1, repeat every 3 weeks; and capecitabine 1000mg/m2, twice daily, d1-d14, repeat every 3 weeks.
During radiotherapy (Monday to Friday), capecitabine was administered at 1650 mg/m2/d, twice a day.
The TV is expanded by 6-7mm to form PTV1, and the CTV is expanded by 6-7mm to form PTV2. The dose of PTV1 was 50Gy/25 times/35 days, and the dose of PTV2 was 45Gy/25 times/35 days, 5 times/week for a total of 5 weeks.
Rate of pCR
rate of pathological complete remission
Time frame: One week after surgery
DFS
Disease free survival
Time frame: 3 years
OS
overall survival
Time frame: 5 years
Started Mar 2022 (actual). Primary completion is estimated for May 2027, 61 months after the start.
Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 61 months is above that.
Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Xelox